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Lifestyle interventions can substantially improve obesity and cardiometabolic risks. How-
ever, evidence of long-term benefits of national intervention is sparse. We aimed to evaluate
the long-term effectiveness of a nationwide program for abdominal obesity.
Methods
A retrospective cohort study was performed using a longitudinal nationwide individual data
in subjects aged 40–74 years who underwent checkups in fiscal year (FY) 2008. Lifestyle
interventions were provided via interview in subjects with abdominal obesity and at least
one cardiometabolic risk factor. Subjects who attended the lifestyle intervention (partici-
pants) were compared to those who did not attend (non-participants). Outcomes were waist
circumferences (WC) and body mass index (BMI) reduction, reversal of metabolic syndrome
(MetS), and changes in cardiometabolic risks. We used a three-step process with robust
analytic approaches to account for selection bias that included traditional multivariate analy-
sis, propensity-score matching and instrumental variable (IV) analyses.
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Results
Of 19,969,722 subjects, 4,370,042 were eligible for analyses; 111,779 participants and
907,909 non-participants. A higher percentage of participants had5% reductions in obe-
sity profiles at year 3, compared to non-participants (WC, 21.4% vs 16.1%; BMI, 17.6% vs
13.6%; p<0.001 each). Participants also had higher reversal for MetS (adjusted odds ratio
1.31; 95% confidence interval: 1.29–1.33; p<0.001). Greater reductions in cardiometabolic
risks were observed in participants. Those results were confirmed in analyses using a pro-
pensity score-matched cohort (n = 75,777, each) and IV analyses. Limitations of this work
include the use of non-randomized national data in Japan to assess the effectiveness of the
nationwide preventive program.
Conclusions
In the nationwide lifestyle intervention for abdominal obesity, the at-risk population achieved
significant reductions in WC, BMI, and cardiometabolic risks in 3 years. This study provides
evidence that the nationwide program effectively achieved long-term improvement in
abdominal obesity and cardiometabolic risks.
Introduction
The worldwide incidence and economic effect of cardiovascular disease (CVD) are substantial.
Healthcare providers must focus on reducing CVD risk factors by helping individuals begin
and maintain lifestyle changes [1].
Published data strongly support the benefits of lifestyle changes as a means to prevent CVD
[1, 2]. Interventions that target lifestyle changes often result in impressive rates of initial behav-
ior changes. However, population changes in lifestyle can be difficult to achieve in clinical
practice [2]. Particularly, behavioral lifestyle changes are frequently not translated into long-
term behavioral changes [3]. Both adoption and maintenance of new cardiometabolic risk-
reducing behaviors pose challenges for many individuals [1]. Therefore, nationwide changes
in healthcare policies are needed to translate the evidence into action and improve CVD pre-
vention at personal, organizational, social, and political levels in many sectors [4–6].
Since April 2008, Japan has embarked on a national health policy change to prevent life-
style-related diseases, such as CVD and diabetes [7]. This comprehensive preventive policy
involves an unprecedented nationwide screening and lifestyle intervention for abdominal obe-
sity with more than 100 million people in a developed country. Health checkups, which
focused on abdominal obesity and cardiometabolic risk factors, were performed annually for
individuals, or their family members, aged 40–74 years and covered as primary beneficiaries
under the health insurance system. From April 2008 to March 2012, 45,313,284 individuals
had specific health checkups, accounting for approximately 86% of the Japanese population of
comparable age.
Here, we evaluated the long-term effectiveness of this nationwide program to prevent
abdominal obesity and CVD risks in a community-based setting. Assessment of the potential
effectiveness of lifestyle intervention requires caution because of selection bias, which could
arise when highly health-conscious or motivated subjects are selected to receive lifestyle inter-
ventions. We therefore used a three-step process with robust analytic approaches to account
MetS ACTION-J study
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for bias that included traditional multivariate analysis, propensity-score matching, and instru-
mental variable (IV) analysis with lifestyle intervention participation rates as the instrument.
Materials and methods
Study design and population
We conducted a nationwide cohort study, known as the Metabolic Syndrome And Compre-
hensive lifesTyle Intervention study On Nationwide database in Japan (MetS ACTION-J) with
retrospectively collected data from the National Database of Health Insurance Claims and Spe-
cific Health Checkups of Japan (NDB). The national data captured examination records and
laboratory data to diagnose MetS. We obtained anonymized data regarding subjects who
underwent a screening program between fiscal year 2008 and fiscal year 2011 from the Minis-
try of Health, Labour and Welfare (MHLW). We have created a database for this study (S1
Appendix). The ethics committees of the University of Kyoto School of Medicine and
National Cerebral and Cardiovascular Center approved the study. Written informed consent
was not obtained due to the retrospective design.
We considered all subjects aged 40–74 years who completed the screening visits in fiscal
year 2008. We excluded subjects who were receiving medications for hypertension or dyslipi-
daemia or diabetes, those who meet the diabetes criteria (fasting blood glucose [FBG]126
and/or hemoglobin A1c [HbA1c]6.5%), those without data required for diagnosing meta-
bolic syndrome (MetS), and those who did not have the specific health checkup in fiscal year
2011.
Screening and lifestyle interventions
All subjects received health checkups, including questionnaires, physical examinations, and
measurements of height and weight, waist circumference (WC), blood pressure, serum choles-
terol, blood glucose, and/or HbA1c. All exams were conducted under an article prescribed by
an ordinance of the MHLW (S2 and S3 Appendices). Smoking status was determined by self-
reported questionnaires. Exams, including anthropometry measurements, blood pressure, and
blood samples, were carried out after at least a 10-hour fast, and the subjects were instructed to
perform no physical activities of moderate or high intensity and to ingest no caffeine and alco-
hol the day before the test. WC was measured at the umbilical level in a standing position
using a tape measure after normal expiration (S2 Appendix). If the umbilical level was dis-
placed downward due to accumulation of abdominal fat, WC was measured at the midpoint
between the superior border of the iliac crest and the inferior margin of the twelfth rib. Blood
pressure was measured twice after at least 5 min rest with the participant seated. Regardless of
the presence/absence of risk, information and advice on CVD prevention were given to all sub-
jects simultaneously with notification of the checkup results annually or more frequently. Spe-
cific health promotion guidance was provided to at-risk individuals. Individuals at risk were
defined as those with a WC85 cm for men and90 cm for women [8] and/or body mass
index (BMI)25 kg/m2 who satisfy at least one of the following requirements: (1) elevated
blood pressure (systolic blood pressure [SBP]130 mmHg or diastolic blood pressure [DBP]
85 mmHg), (2) dyslipidaemia (triglycerides [TG]150 mg/dl or high-density lipoprotein
[HDL]-cholesterol <40 mg/dl), and/or (3) impaired glucose tolerance (FBG100 mg/dl or
HbA1c5.6%). After subjects with risks received health checkup results by mail or other
means, they reserved counselling sessions themselves. Health promotion guidance was pro-
vided via interview by healthcare providers (physician, health nurse, or managerial dietician)
with or without additional continuous support for 3 months or longer in response to individ-
ual risks (Table 1 and S3 Appendix).
MetS ACTION-J study
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Statistical analysis
We evaluated WC and BMI reduction, and reversal of MetS using logistic regression mod-
els and changes in cardiometabolic risk factors using linear regression models to investi-
gate associations between lifestyle intervention and cardiometabolic risk factors. Since
previous studies have shown that a loss of 5–10% of initial weight is associated with signifi-
cant reductions in cardiovascular risks, a 5% reduction was considered clinically meaning-
ful [9]. Reversal of MetS was defined as normalization for subjects with MetS [8] and risk
reduction for subjects with pre-MetS. We performed regression analysis with coefficients
expressed per one standard deviation (SD) to compare intervention effect size directly
among cardiometabolic risk factors. Covariates included age, sex, and smoking status as
categorical variables, and BMI (except the WC model) and baseline individual component
level as continuous variables. In addition to adjusting for covariates, we performed rigor-
ous adjustment for baseline variables using propensity-score matching. The propensity
score was calculated from a multivariate probit regression model in the whole cohort that
included demographic characteristics and cardiometabolic risk factors. Matching was per-
formed using a 1:1 matching protocol within a calliper of 0.01 SD of the propensity score
probit.
We performed IV analysis to provide estimates that would remain unbiased even if impor-
tant confounding variables were not measured [10]. We used the facility level ratio of lifestyle
intervention, in which the facility intervention ratio was defined as the number of intervention
participants divided by the total number of candidates, as the instrument. Similar instruments
have previously been reported [11]. In this study, it is unlikely that the facility ratios of lifestyle
intervention would be associated with clinical improvements in any way other than the
Table 1. Nationwide preventive program: Screening and lifestyle intervention features.
Health checkups
Subjects
- All individuals or their family members aged 40–74 years, who are covered as primary beneficiaries under the health insurance system in Japan.
- Pregnant women, prisoners, individuals living overseas, and long-term inpatients were excluded.
Exams
- Exams included questionnaires, physical examinations, waist circumference, height, weight, blood pressure, blood samples, and urinalyses.
- All exams were conducted under an article prescribed by an ordinance of the Ministry of Health, Labour and Welfare.
Results & Information Supply
- Regardless of the presence/absence of cardiometabolic risks, information was given to all subjects simultaneously, with notification of the checkup results annually
or more frequently.
Lifestyle interventions
- Individuals with a waist circumference85 cm (men)/90 cm (women) or <85 cm (men)/<90 cm (women) with a body mass index25 kg/m2, with at least one
of the following: (1) high glucose tolerance (fasting blood glucose100 mg/dl or hemoglobin A1c5.6%), (2) dyslipidemia (triglyceride 150 mg/dl or high-density
lipoprotein-cholesterol <40 mg/dl), (3) high blood pressure (systolic blood pressure130 mm Hg or diastolic blood pressure85 mm Hg) were considered at risk.
- Individuals taking medications for hypertension, dyslipidemia, or diabetes mellitus were excluded.
Interventions
- Interventions were provided for 20 minutes or more to each individual separately or for 80 minutes or more to a group by a physician, public health nurse, or
registered dietician.
- The facilitator explained the necessity of lifestyle improvement, the relationship between lifestyle and the specific health checkup data, the patient’s lifestyle,
knowledge about metabolic syndrome and lifestyle-related chronic diseases, and the influence of these factors on the daily lives of the individuals receiving the
motivational support.
- Explanation was given about the advantages of lifestyle improvement and the disadvantages of failing to improve lifestyle.
- The facilitator suggested changes needed to improve the lifestyle (e.g., diet and exercise).
- The facilitator set goals for actions and the timing of the outcome evaluation, accompanied by presentation of the social resources needed for lifestyle improvement
and support for their effective utilization.
- The facilitator showed how to measure body weight and abdominal circumference.
- Goals for actions and the action plan were prepared by the individual receiving the motivational support under guidance via interview.
- A follow-up interview was performed based on the risks.
- The evaluation was made via interview or telecommunication (telephone, e-mail, etc.), 6 months after the first session.
https://doi.org/10.1371/journal.pone.0190862.t001
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participants of intervention. To confirm that the ratio of lifestyle intervention was not a weak
instrument, we used a partial F test and found sufficiently large F statistics. Patients seen at
institutions with an intervention rate less than 0.1% and over 60% were excluded from the IV
analysis, since lifestyle intervention choice may have been decided less by facility preference
and therefore be subject to confounding by unmeasured subject-level covariates [12]. We eval-
uated the balance of measured covariates across levels of the IV to provide additional informa-
tion to assess its validity (S2 Table). Using two-stage linear regression for the calculation of the
coefficients, we estimated IV-adjusted changes of cardiometabolic factors with the IV being
the facility intervention rate, using the STATA procedure IVREG. Covariates include geo-
graphic location and clinical characteristics, including urban or rural (S4 Appendix), age, sex,
smoking status, BMI (except the WC), and baseline individual component level. The analyses
were conducted using STATA, 13.1 (STATA Corp., College Station, Texas) and SAS 9.2 (SAS
Institute, Cary, North Carolina).
Results
Study population
We included subjects (n = 19,969,722) aged 40–74 years who completed the screening visits
in the first year (from April 2008 to March 2009). Among this population, we excluded
15,599,680 subjects who were receiving medications for hypertension or dyslipidemia or dia-
betes (n = 5,051,629), those who meet diabetes criteria (n = 417,450), those without appropri-
ate data required for diagnosing MetS (n = 1,793,327), those with data error (n = 879,889), and
those who did not have the specific health checkup in fiscal year 2011 (n = 7,457,385). Of
4,370,042 subjects who were eligible for analyses, 3,350,354 (76.7%) were eligible for healthcare
guidance (information supply only), and 1,019,688 (23.3%) were eligible for the interventional
program. Totally, 111,779 subjects attended the health guidance program (participants), and
907,909 did not (non-participants) (Fig 1).
At baseline, the mean (SD) WC and BMI were 91.2 (5.9) cm and 26.2 (2.5) kg/m2 for partic-
ipants and 91.2 (5.7) cm and 26.1 (2.4) kg/m2 for non-participants, respectively. Non-partici-
pants had slightly worse blood pressures and lipid profiles than participants (Table 2). After
propensity-score matching was performed for the entire population, there were 75,777
matched pairs. The absolute standardized differences were <10% for all variables entered into
the propensity score, indicating adequate matches [13].
Effectiveness of nationwide lifestyle intervention
Clinically relevant reductions, i.e.,5% at year 3, were achieved in a significantly higher per-
centage of participants compared to non-participants (WC, 21.4% vs 16.1% and BMI, 17.6% vs
13.6%; p<0.001, each; Fig 2). Advanced weight reductions (10%) were also observed in a sig-
nificantly higher percentage of participants. Both abdominal and overall obesity, measured by
categorical weight reductions, improved significantly in participants compared to non-partici-
pants. Participants who received lifestyle intervention had significantly improvements in
MetS, as compared with non-participants (reversal of MetS: 47.0% vs. 41.5%, p<0.001). Analy-
sis in the matched cohort showed similar results (S1 Fig).
After we adjusted for confounders, lifestyle intervention was associated with an adjusted
odds ratio (OR) 1.33 (95% confidence interval [CI]: 1.31–1.36, p<0.001) for 5% of WC reduc-
tion, 1.36 (95% CI 1.33–1.38, p<0.001) for 5% of BMI reduction, and 1.33 (95% CI: 1.31–1.33,
p<0.001) for reversal of MetS (Table 3). Confirmatory analyses in a propensity-matched
cohort yielded no substantive differences relative to traditional multivariate analyses (Table 3).
MetS ACTION-J study
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The mean WC changes were −1.34 and −0.44 cm in participants and non-participants,
respectively, with a difference of −0.89 cm (95% CI: −0.92 to −0.86). The mean BMI changes
were −0.29 and −0.08 kg/m2 in participants and non-participants, respectively, with a differ-
ence of −0.22 kg/m2 (95% CI: −0.22 to −0.21). The intervention program also resulted in sig-
nificantly greater reductions in both abdominal and overall obesity parameters (S1 Table).
Participants, compared to non-participants, had significant reductions in systolic blood pres-
sure (SBP, −1.15 vs −0.72 mm Hg), diastolic blood pressure (DBP, −0.97 vs −0.64 mm Hg),
and log TG (−0.11 vs −0.08), respectively (p<0.001 for each). Participants also improved their
HDL-cholesterol level more than non-participants (1.48 vs 0.94 mg/dl). Of all parameters for
obesity and cardiometabolic risk factors, greater reductions were observed in abdominal and
Fig 1. Study flow chart. FY, fiscal year.
https://doi.org/10.1371/journal.pone.0190862.g001
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overall obesity profiles, compared to cardiometabolic parameters. The adjusted differences in
the traditional adjusted model were attenuated (ΔWC coefficient: −0.76; 95% CI: −0.79 to
−0.73; ΔBMI coefficient: −0.19; −0.20 to −0.18), and the coefficients in the propensity-matched
cohort were further attenuated (ΔWC: −0.77; −0.82 to −0.72; ΔBMI: −0.20; −0.21 to −0.18; Fig
3). The IV model strengthened the findings of the traditional adjusted model (Fig 3). Similar
patterns were found for other cardiometabolic risk factors.
Discussion
This study examined the effectiveness of a nationwide preventive program, which is comprised
of screening, counselling, and education, using national “real world” data. Nationwide lifestyle
intervention is effective in achieving clinically relevant reductions in WC and BMI and rever-
sal of MetS. This intervention was also effective for long-term changes in cardiometabolic risk
factors.
MetS is widely used to identify patients with abdominal obesity who have increased risk for
CVD and diabetes [14]. While metabolic components likely overlap [15], we previously
demonstrated that abdominal obesity is an independent predictor for new onset of individ-
ual MetS components in the longitudinal study [16]. In a previous study, abdominal obesity
Table 2. Baseline characteristics.
Characteristics No-risk group (eligible for healthcare
guidance)
At-risk group





P value (Non-participants vs.
participants)
n 3 350 354 907 909 111 779
Age, %
40–44 27.4 24.9 18.9 −14.4 <0.001
45–49 23.3 24.1 19.8 −10.4
50–54 18.9 21.7 18.0 −9.2
55–59 12.2 13.9 13.2 −2.1
60–64 7.6 6.5 10.2 13.4
65–69 8.1 6.6 14.6 26.0
70 2.5 2.3 5.3 15.8
Men, % 51.6 82.4 77.8 11.5 <0.001
Smoking, % 25.0 34.9 28.4 14.0 <0.001
WC, cm 78.1 (7.1) 91.2 (5.9) 91.2 (5.7) −1.0 0.001
BMI, kg/m2 21.6 (2.4) 26.2 (2.5) 26.1 (2.4) −5.9 <0.001
SBP, mm Hg 118.2 (15.6) 130.7 (15.9) 130.6 (15.4) −0.5 0.154
DBP, mm Hg 73.1 (10.7) 82.2 (11.0) 81.2 (10.5) −9.9 <0.001
TG, mg/dl b 82 (60–116) 147 (99–201) 141 (96–
195)
−5.1 <0.001
HDL, mg/dl 66.3 (16.0) 54.0 (13.2) 54.1 (13.1) 0.8 0.017
HbA1c, % c 5.4 (0.3) 5.5 (0.4) 5.6 (0.4) 3.7 <0.001
FBG, mg/dl c 91.7 (8.6) 98.2 (9.8) 97.7 (9.6) −5.0 <0.001
a Standardized difference is the mean difference divided by the pooled standard deviation, expressed as a percentage.
b Standardized differences were calculated using log-transformed triglyceride.
c FBG or HbA1c or both can be measured in the program.
WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL, high-density lipoprotein
cholesterol; HbA1c, hemoglobin A1c; and FBG, fasting blood glucose.
https://doi.org/10.1371/journal.pone.0190862.t002
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Fig 2. Categorical waist and weight reduction. WC, waist circumference; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0190862.g002
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was found to be important in MetS development and preceded the development of other
MetS components [17, 18]. Other researchers showed that abdominal obesity is superior to
overall obesity for predicting total and cardiovascular mortality rates, suggesting that a
reduction in abdominal obesity should reduce the risk of MetS and negative cardiovascular
outcomes [19, 20].
A health promotion program focusing on lifestyles can substantially reduce obesity and
CVD risk. However, the findings from previous reports have been equivocal. Despite the
potentially large benefits of obesity reduction, lifestyle interventions have had small long-term
success, especially at the population level [7, 21, 22]. In a previous meta-analysis, lifestyle inter-
ventions significantly reduced blood pressure and low-density lipoprotein cholesterol in the
general population, but the pooled estimates have dubious validity because of marked unex-
plained heterogeneity among trials (I2 statistic >85%) [23, 24]. In the present study, we have
shown long-term improvement in reducing obesity and cardiometabolic risk factors through
lifestyle intervention within the framework of nationwide policy. These findings add further
real-world evidence that suggests the nationwide preventive program that focuses on abdomi-
nal obesity was truly effective.
Although the randomized controlled study (RCT) unquestionably remains a powerful tool
to minimize the risk of bias due to confounding factors and to develop scientific evidence, the
usefulness of real-world evidence is emphasized through its potential for complementing the
knowledge gained from clinical trials [25], where limitations make it difficult to generalize
findings to larger nationwide settings [26]. In a previous population-based randomized life-
style intervention study (the Inter99 study) [27], screening and lifestyle counselling had sus-
tained effects on physical activity and dietary habits after the intervention discontinuation [28]
and changes in physical activity level from baseline to 5-year follow-up were associated with
relevant changes in weight, WC, DBP and serum lipids [29]. Nevertheless, there was no effect
on incidence of diabetes [30] and development of fatal and non-fatal ischemic heart disease in
the general population [31]. As the author discussed in the limitations, a 10-year follow-up
Table 3. Clinical end point in a whole cohort and a propensity-matched cohort.
Unadjusted Adjusted a Propensity-matched cohort
Odds ratios (95% CI) P value Odds ratios (95% CI) P value Odds ratios (95% CI) P value
Clinically relevant reduction (5%) in
WC 1.42 (1.39–1.44) <0.001 1.33 (1.31–1.36) <0.001 1.36 (1.33–1.40) <0.001
BMI 1.36 (1.34–1.39) <0.001 1.36 (1.33–1.38) <0.001 1.38 (1.34–1.42) <0.001
Significant reduction (10%) in
WC 1.33 (1.29–1.37) <0.001 1.24 (1.20–1.27) <0.001 1.28 (1.21–1.34) <0.001
BMI 1.23 (1.20–1.27) <0.001 1.28 (1.24–1.32) <0.001 1.34 (1.27–1.42) <0.001
Reduction in
WC 1.40 (1.38–1.42) <0.001 1.33 (1.32–1.35) <0.001 1.33 (1.31–1.36) <0.001
BMI 1.38 (1.36–1.40) <0.001 1.32 (1.30–1.33) <0.001 1.31 (1.29–1.34) <0.001
Reversal of MetS
Reversal of MetS 1.33 (1.32–1.35) <0.001 1.31 (1.29–1.33) <0.001 1.27 (1.24–1.30) <0.001
a The control (non-participants) group is referent. WC; adjusted for age, sex, smoke, and waist circumferences at baseline. BMI; adjusted for age, sex, smoke, and body
mass index at baseline. Reversal of MetS; adjusted for age, sex, body mass index, smoke, systolic blood pressure, log triglycerides, HDL-cholesterol, and HbA1c.
WC, waist circumference; BMI, body mass index; MetS, metabolic syndrome; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0190862.t003
MetS ACTION-J study
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could be too short to consider CVD. However, it is still early to conclude, based only on the
randomized controlled trials [23, 31], if health checks followed by lifestyle counselling in a gen-
eral population should not be part of a country’s health policy. Traditional RCTs are often con-
ducted with specific populations and in a specialized environment that differ significantly
from the realities of a public health policy setting and therefore RCTs might not provide a real-
istic view of policy impact for the general population [25]. Comprehensive and integrated pub-
lic health prevention methods ideally attempt to implement multifaceted measures at each
level of the health impact pyramid, which consists of five tiers: (1) socioeconomic factors; (2)
changing the context to create healthy default decisions in the individual; (3) long-lasting pro-
tective interventions; (4) clinical interventions; and (5) counselling and education [32]. The
Japanese national health policy is in line with the ideal of clinical care impacting population
health. All Japanese people of the targeted age have equal opportunities to receive health check-
ups and lifestyle interventions under the law (tiers 1 and 5). The annual health checkup enables
continuous monitoring (tier 3). Individuals at risk of developing CVD can receive counselling
and educational interventions (tier 5), which can connect them to appropriate medical treat-
ment (tier 2). The greatest differences between RCT and a public health policy setting is that
the nationwide policy enables almost all citizens to learn the term “metabolic syndrome,” sug-
gesting that it may be able to change the context of health by altering social norms (tiers 4 and
5). Moreover, this action has been conducted at the country level and led by the government,
as recommended by the World Health Organization [33]. Therefore, the lifestyle intervention
has maximized synergy, and we have achieved long-term success. In our analysis, we provide
evidence that by implementing interventions, sustained public health and clinical benefits, as
set forth at the beginning of the study, can be achieved. This study can lead to other successful
population-based prevention strategies in a national policy context. Thus, the national lifestyle
intervention can continue to yield a substantial and sustained reduction in abdominal obesity
and cardiometabolic risk factors.
Our study had several limitations. Evaluating the effectiveness of the lifestyle interventions
using non-randomized data has been controversial because of potential biases related to treat-
ment selection (attending the lifestyle intervention or not) and the lack of data on potential
confounding variables, including socioeconomic status, income, education, health literacy, or
health motivation. The previous report suggested that there are two reasons for not attending
the lifestyle interventions. Subjects may already have regular office visits, and subjects may not
have time to attend the intervention. In the former scenario, non-participants must initiate
lifestyle changes at their clinic, resulting in underestimated effectiveness of nationwide inter-
vention. In the latter scenario, non-participants are not always less motivated than partici-
pants. Since participation increased more than doubled by shortening the intervention session
time in the previous study, some non-participants may be willing to change their lifestyles on
their own. Therefore, the latter reason may lead to either underestimation or overestimation of
the intervention effect. To mitigate bias, we used three steps to assess intervention effective-
ness. First, we controlled for demographic and clinical factors using a traditional multivariate
model. Secondly, we used propensity-score matching to further control for selection bias. We
applied all possible data believed to potentially affect the decision to attend lifestyle counselling
in an effort to maximally reduce selection bias, which carefully balanced observed baseline
characteristics [34]. If the distribution of unmeasured factors is more likely to be similar with
similar clinical indications and risk when considering therapies, unmeasured factors can
Fig 3. Beta-coefficients of each cardiometabolic risk factors using linear regression and instrumental variable methods. SBP, systolic blood pressure;
DBP, diastolic blood pressure; PS, propensity score; IV, instrumental variable.
https://doi.org/10.1371/journal.pone.0190862.g003
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closely correlate with measured factors. In this setting, propensity scores may remove bias due
to treatment selection differences resulting from unmeasured factors [10]. When strong selec-
tion bias exists, however, both multivariate adjustment and propensity-based matching are no
more likely to remove bias due to unmeasured confounding variables. Thirdly, we have added
IV analyses, which is a method designed to control for unmeasured bias. Our finding that sev-
eral baseline characteristics modified the comparative effectiveness of lifestyle intervention is
also consistent with the results of all analytical steps. Our analyses of nationwide observational
data can provide reliable estimates of real-world lifestyle intervention effectiveness [35].
The second limitation includes the natural constraints of national data. Although a consis-
tent format was used to collect data, the reported data were subject to data error and local vari-
ability. However, it was unlikely that the groups (i.e., participants and non-participants) would
be differentially affected. Third, our subjects were selected based on attending checkups in
both the first year and fiscal year 2011, indicating that they were health-conscious individuals.
Our follow-up was 3 years, and the effects may attenuate over time. Fourth, we could not eval-
uate specific program features including individual vs. group sessions or physical activity vs.
diet vs. both. Future research needs to identify which features optimize the effectiveness of
the programs and which are less critical [36]. Fifth, the smoking status may be under-reported
in self-answered questionnaires. Finally, the generalizability of our findings to other countries
or ethnic groups with a higher burden of obesity and adverse cardiometabolic diseases is
unknown. The aspects of Japanese culture may have contributed to our results, including the
factors that already contribute to the very low obesity prevalence in Japan compared to other
nations. It can also be difficult to adopt the current estimates worldwide due to a different
MetS criteria in Japan. However, the United States Preventive Services Task Force recom-
mends screening all adults for obesity and offering or referring obese adults to intensive behav-
ioral interventions to improve weight status and other risk factors for important health
outcomes [2]. In Finland, cardiovascular risk factor levels declined markedly after the imple-
mentation of a national CVD prevention strategy during the late 1970s [37]. Recently, the
comprehensive healthy lifestyle program, comprising preventive and promotional activities
that consider both population and high-risk approaches, has been applied to a middle-income
country [38]. These studies introduce possible beneficial effects of nationwide lifestyle inter-
ventions in developed and developing countries. Further research is required to evaluate the
long-term cost-effectiveness of a nationwide screening and lifestyle intervention. Clinical
effectiveness and cost effectiveness underpinned by the best clinical evidence should be dis-
cussed in parallel [39].
In conclusion, the national screening and lifestyle intervention yielded a substantial and
sustained improvement in abdominal obesity and reversal of MetS.
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